Prognostic factors for predicting severity and mortality in hospitalized COVID‐19 patients

Aljohani, Fahad Dakilallah; Khattab, Amin; Elbadawy, Hossein M.; Alhaddad, Aisha; Alahmadey, Ziab; Alahmadi, Yaser M.; Eltahir, Heba M.; Matar, Heba M.; Wanas, Hanaa

doi:10.1002/jcla.24216

Cited by 10 publications

(5 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Though our study observed a higher ferritin level in non‐survivor patients, it did not prove it as a significant risk factor of ICU admission or mortality when adjusted for other factors. This observation has similarity with other studies (Aljohani et al, 2022; Carubbi et al, 2021) but contrast with other study where higher ferritin is said to be a risk factors of severe disease and mortality (Ahmed et al, 2021).…”

Section: Discussionsupporting

confidence: 90%

Predictors of mortality and ICU requirement in hospitalized COVID‐19 patients with diabetes: A multicentre study

et al. 2022

View full text Add to dashboard Cite

Aim This study aimed to identify the predictors of mortality and ICU requirements in hospitalized COVID‐19 Patients with Diabetes. Design Cross‐sectional study. Methods It was a retrospective study of patients hospitalized with COVID‐19 infection from October 2020–February 2021 in four hospitals in Sylhet, Bangladesh. Logistic regression analysis was applied to explore the predictors of ICU requirement and in‐hospital mortality. Results In the whole cohort (n = 500), 11% of patients died and 24% of patients required intensive care unit (ICU) support. Non‐survivors had significantly higher prevalence of lymphopenia, thrombocytopenia and leukocytosis. Significant predictors of in‐hospital mortality were older age, neutrophil count, platelet count and admission peripheral capillary oxygen saturation (SpO2). Older age, ischemic heart disease, WBC count, D‐dimer and admission SpO2 were identified as significant predictors for ICU requirement. Patient or Public Contribution No.

show abstract

Section: Discussionsupporting

confidence: 90%

Predictors of mortality and ICU requirement in hospitalized COVID‐19 patients with diabetes: A multicentre study

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In this study, we evaluated plasma CK-BB levels to detect neurological damage that may develop with the severity of COVID-19 pneumonia. In previous studies, parameters such as ferritin, CRP, pro-BNP, troponin-I, fibrinogen, d-dimer, neutrophil-lymphocyte ratio, procalcitonin, and IL-6 were found to be prognostic biomarkers in COVID-19 pneumonia (30)(31)(32). In our study, these biomarkers were found to be high in intensive care patients with severe pneumonia symptoms (p<0.01), while serum CK-BB levels did not change (p>0.05).…”

Section: Discussionsupporting

confidence: 55%

Evaluation of the Development of Neurological Damage in Severe Covid-19 Pneumonia With Serum Ck-Bb Levels

Erdem,

Orhan,

Güner

et al. 2024

qrheumatol

View full text Add to dashboard Cite

Aim: Aim: Despite numerous reports of various neurological symptoms observed in Coronavirus disease-2019 (COVID-19) disease, the role of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) in the neuropathogenesis and tropism of the central nervous system (CNS) has yet to be fully elucidated. In this study, we evaluated the development of CNS damage related to the severity of COVID-19 pneumonia with creatine kinase BB (CK-BB) serum levels. Material and Methods:Material and Methods: The study included 55 patients hospitalized in the intensive care unit diagnosed with severe COVID-19 pneumonia, 79 in the inpatient service diagnosed with milder COVID-19 pneumonia, and 39 healthy volunteers. CK-BB levels were measured using a quantitative sandwich enzyme immunoassay technique with an Enzyme-Linked Immunosorbent Assay kit. Detection of SARS-CoV-2 was performed by real time-polymerase chain reaction from the respiratory tract (nasopharyngeal swab) according to current guidelines.Results: Results: While markers that were shown to predict disease severity were higher in patients with severe COVID-19 pneumonia compared with patients with milder pneumonia and the control group, serum levels of the neurological damage marker CK-BB were found to be similar between the groups [respectively 6.84 (5.05-16.2), 7.48 (4.7-22.5), 6.7 (3.8-16.2), p>0.005]. In addition, there was no difference in serum CK-BB levels between patients who developed neurological symptoms and those who did not [respectively 6.78 (5.07-17.21), 7.43 (4.7-22.5), p>0.005]. Conclusion: Conclusion:In COVID-19 pneumonia, serum CK-BB levels do not increase with disease severity and the development of neurological symptoms.

show abstract

“…The COVID-19 pandemic remains a public health emergency of global significance that threatens human health and welfare [ 19 ]. Therefore, in this retrospective cohort study, clinical and laboratory data from 300 confirmed cases of COVID-19 admitted to the Hospital Nacional Almanzor Aguinaga Asenjo (HNAAA) in Peru were analyzed.…”

Section: Discussionmentioning

confidence: 99%

Factors associated with mortality in patients hospitalized for COVID-19 admitted to a tertiary hospital in Lambayeque, Peru, during the first wave of the pandemic

et al. 2023

View full text Add to dashboard Cite

Introduction COVID-19 caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has spread worldwide, becoming a long-term pandemic. Objectives To analyze the factors associated with mortality in patients hospitalized for COVID-19 in a tertiary hospital in the Lambayeque region of Peru. Methods A retrospective cohort study of patients with a diagnosis of COVID-19, hospitalized in a hospital in northern Peru, was conducted from March to September 2020. Results Of the 297 patients studied, 69% were women, the mean age was 63.99 years (SD = ±15.33 years). Hypertension was the most frequent comorbidity (36.67%), followed by diabetes mellitus (24.67%) and obesity (8.33%). The probability of survival at 3 days of ICU stay was 65.3%, at 7 days 24.2%, and 0% on day 14. Risk factors associated with mortality in patients hospitalized for COVID-19 are age, male sex, tachypnea, low systolic blood pressure, low peripheral oxygen saturation, impaired renal function, elevated IL-6 and elevated D-dimer. Conclusions Mortality in hospitalized patients with COVID-19 was 51.18 per 100 persons, Mortality was found to be associated with hypertension, type of infiltrating, and sepsis.

show abstract

Prognostic factors for predicting severity and mortality in hospitalized COVID‐19 patients

Cited by 10 publications

References 36 publications

Predictors of mortality and ICU requirement in hospitalized COVID‐19 patients with diabetes: A multicentre study

Predictors of mortality and ICU requirement in hospitalized COVID‐19 patients with diabetes: A multicentre study

Evaluation of the Development of Neurological Damage in Severe Covid-19 Pneumonia With Serum Ck-Bb Levels

Factors associated with mortality in patients hospitalized for COVID-19 admitted to a tertiary hospital in Lambayeque, Peru, during the first wave of the pandemic

Contact Info

Product

Resources

About